RUclips timestamps by Les Faby (partial) 01:26 Why did we need a new OPV? 04:56 David Baltimore and Vincent Racaniello show genome and suggest the vaccine could be redesigned to avoid reversion to virulence revising existing vaccines not glamorous but critical advantages of an oral live attenuated vaccine What changes made in NOPV candidates 25:51 Type 2 polio strain 30:55 first NOPV study was with ipv vaccinated subjects to limit risk of getting polio. Audio podcast timestamps by Jolene. Thanks!
Such an intriguing episode! We extend our heartfelt gratitude to Vincent for introducing us to these remarkable scientists, who have eloquently elucidated their journey to develop the groundbreaking novel oral poliovirus vaccine. The virologists who contributed to the research that laid the foundation for this innovative vaccine undoubtedly merit consideration for a Nobel Prize.
Thank you for your comments about the tOPV-bOPV switch in 2016. Yes we should have moved to IPV schedules in countries that eliminated wild poliovirus but price of IPV & its logistics were prohibitive for many low income and even middle income countries. I like the idea of a novel trivalent OPV. Keith Feldon
Hello from Chiang Mai! I have worked on polio eradication in the field since 1994 in several countries including India, Pakistan and Nigeria and have worked on cVDPV outbreaks in the Philippines, Papua New Guinea and Indonesia. Actually VAPP is an individual reaction and side effect to oral polio vaccine and not the same as cVDPV which is the result of low population immunity to the type of polio virus and also a result of inadequate surveillance that does not pick up the mutations in vaccine virus. Novel OPV is an improvement but does not completely eliminate risk for mutations. It is a question of doing the best for the most amount of people. It may be best to go to all inactivated polio vaccine schedule except for outbreak response which requires OPV to bestow more gut immunity. Thank you, Keith Feldon
interesting post. The question of reversion wrt circulating vaccine derived polio is fascinating. Obviously the vaccine rate of OPV is enough to suppress and wipe out wild polio strains. So it does effect the reproduction numbers. So does NOPV reduce R at all? At rates superior/worse than classic OPV? Also like the point that if OPV was used in a batch fashion, population wise, things would be better.
Also it has been a great challenge to communicate to communities that the solution to outbreaks of cVDPV is to get high coverage with OPV in 2-3 campaign rounds or even more times. Thank you, Keith Feldon
RUclips timestamps by Les Faby (partial)
01:26 Why did we need a new OPV?
04:56 David Baltimore and Vincent Racaniello show genome
and suggest the vaccine could be redesigned to avoid reversion to virulence
revising existing vaccines not glamorous but critical
advantages of an oral live attenuated vaccine
What changes made in NOPV candidates
25:51 Type 2 polio strain
30:55 first NOPV study was with ipv vaccinated subjects to limit risk of getting polio.
Audio podcast timestamps by Jolene. Thanks!
Such an intriguing episode! We extend our heartfelt gratitude to Vincent for introducing us to these remarkable scientists, who have eloquently elucidated their journey to develop the groundbreaking novel oral poliovirus vaccine. The virologists who contributed to the research that laid the foundation for this innovative vaccine undoubtedly merit consideration for a Nobel Prize.
Learned so much, what a treat to hear these scientists discuss this in detail.
Fascinating discussion. Thank you all for making the world a smarter place.
I so agree. Listening for a second time.
Discussion and debate at its best. Great work Vincent.
Thank you for this very informative episode! Much appreciated.
Thank you for your comments about the tOPV-bOPV switch in 2016. Yes we should have moved to IPV schedules in countries that eliminated wild poliovirus but price of IPV & its logistics were prohibitive for many low income and even middle income countries. I like the idea of a novel trivalent OPV.
Keith Feldon
Hello from Chiang Mai! I have worked on polio eradication in the field since 1994 in several countries including India, Pakistan and Nigeria and have worked on cVDPV outbreaks in the Philippines, Papua New Guinea and Indonesia. Actually VAPP is an individual reaction and side effect to oral polio vaccine and not the same as cVDPV which is the result of low population immunity to the type of polio virus and also a result of inadequate surveillance that does not pick up the mutations in vaccine virus. Novel OPV is an improvement but does not completely eliminate risk for mutations. It is a question of doing the best for the most amount of people. It may be best to go to all inactivated polio vaccine schedule except for outbreak response which requires OPV to bestow more gut immunity.
Thank you,
Keith Feldon
Why atenuated virus subinfection produce strongest immunity ?
Did we need new adjuvants for inactivated viruses?
interesting post. The question of reversion wrt circulating vaccine derived polio is fascinating. Obviously the vaccine rate of OPV is enough to suppress and wipe out wild polio strains. So it does effect the reproduction numbers. So does NOPV reduce R at all? At rates superior/worse than classic OPV? Also like the point that if OPV was used in a batch fashion, population wise, things would be better.
Also it has been a great challenge to communicate to communities that the solution to outbreaks of cVDPV is to get high coverage with OPV in 2-3 campaign rounds or even more times.
Thank you,
Keith Feldon
August 3rd …
LOU! sah? VARIANT! you? GEN-X!!!!
01:19:25 Old joke. The operation was a success, but the patient died.
Online news article "More polio cases now caused by v than by wild virus" by The Associated Press
And you still don't understand the topic.